Reata Pharmaceuticals: A Successful Treatment for Alport Syndrome

Reata Pharmaceuticals CARDINAL Study Met Primary and Key Secondary Endpoints
Reata Pharmaceuticals (RETA) announced that the Phase 3 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) caused by Alport syndrome met its primary and key secondary endpoints.  

This news is surely music in the ears of families with members . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.